Thomas Langbein

1.2k total citations
37 papers, 775 citations indexed

About

Thomas Langbein is a scholar working on Radiology, Nuclear Medicine and Imaging, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Thomas Langbein has authored 37 papers receiving a total of 775 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Radiology, Nuclear Medicine and Imaging, 25 papers in Pulmonary and Respiratory Medicine and 16 papers in Oncology. Recurrent topics in Thomas Langbein's work include Radiopharmaceutical Chemistry and Applications (26 papers), Prostate Cancer Treatment and Research (25 papers) and Peptidase Inhibition and Analysis (10 papers). Thomas Langbein is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (26 papers), Prostate Cancer Treatment and Research (25 papers) and Peptidase Inhibition and Analysis (10 papers). Thomas Langbein collaborates with scholars based in Germany, United States and Thailand. Thomas Langbein's co-authors include Matthias Eiber, Wolfgang Weber, Richard P. Baum, Harshad Kulkarni, Christiane Schuchardt, Aviral Singh, Gerd Fabian Volk, Alexander Wurzer, H. Sonntag and Dorothea Trapp and has published in prestigious journals such as International Journal of Molecular Sciences, British Journal of Anaesthesia and World Journal of Gastroenterology.

In The Last Decade

Thomas Langbein

35 papers receiving 758 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Langbein Germany	14	498	445	209	50	48	37	775
Jeffrey C. Buchsbaum United States	23	286 0.6×	708 1.6×	166 0.8×	45 0.9×	190 4.0×	58	1.2k
Andrea L. DiCarlo United States	20	755 1.5×	285 0.6×	123 0.6×	122 2.4×	231 4.8×	49	1.1k
Marijke De Saint‐Hubert Belgium	20	380 0.8×	466 1.0×	133 0.6×	70 1.4×	237 4.9×	72	1.1k
R. Gahbauer United States	19	665 1.3×	482 1.1×	118 0.6×	44 0.9×	65 1.4×	63	1.2k
Michael Makar United States	11	393 0.8×	283 0.6×	51 0.2×	23 0.5×	35 0.7×	41	710
Stephan Maus Germany	20	851 1.7×	719 1.6×	284 1.4×	64 1.3×	91 1.9×	67	1.1k
Michael S. Petronek United States	11	164 0.3×	309 0.7×	79 0.4×	40 0.8×	103 2.1×	43	584
Allison Gibbs United States	11	531 1.1×	250 0.6×	114 0.5×	78 1.6×	130 2.7×	18	619
Steffie M. B. Peters Netherlands	13	406 0.8×	198 0.4×	124 0.6×	36 0.7×	30 0.6×	32	523
Fadi Khreish Germany	17	710 1.4×	686 1.5×	270 1.3×	84 1.7×	54 1.1×	46	867

Countries citing papers authored by Thomas Langbein

Since Specialization

Citations

This map shows the geographic impact of Thomas Langbein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Langbein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Langbein more than expected).

Fields of papers citing papers by Thomas Langbein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Langbein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Langbein. The network helps show where Thomas Langbein may publish in the future.

Co-authorship network of co-authors of Thomas Langbein

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Langbein. A scholar is included among the top collaborators of Thomas Langbein based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Langbein. Thomas Langbein is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Singh, Aviral, et al.. (2025). The PANEN nomogram: clinical decision support for patients with metastatic pancreatic neuroendocrine neoplasm referred for peptide receptor radionuclide therapy. Frontiers in Endocrinology. 16. 1514792–1514792.

Tauber, Robert, Karina Knorr, Margitta Retz, et al.. (2023). Safety and Efficacy of [¹⁷⁷Lu]-PSMA-I&T Radioligand Therapy in Octogenarians with Metastatic Castration-Resistant Prostate Cancer: Report on 80 Patients over the Age of 80 Years. Journal of Nuclear Medicine. 64(8). 1244–1251. 11 indexed citations

Ilhan, Harun, Markus Kroenke, Alexander Wurzer, et al.. (2022). ¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Curative-Intent Radiation Therapy: A Bicentric Retrospective Study. Journal of Nuclear Medicine. 63(8). 1208–1214. 4 indexed citations

Langbein, Thomas, Hui Wang, Isabel Rauscher, et al.. (2022). Utility of ¹⁸F-rhPSMA-7.3 PET for Imaging of Primary Prostate Cancer and Preoperative Efficacy in N-Staging of Unfavorable Intermediate- to Very High-Risk Patients Validated by Histopathology. Journal of Nuclear Medicine. 63(9). 1334–1342. 19 indexed citations

Lunger, Lukas, Maythinee Chantadisai, Isabel Rauscher, et al.. (2022). Prognostic Role of⁶⁸Ga-PSMA11 PET–Based Response in Patients with Prostate Cancer Undergoing Taxane-Based Chemotherapy. Journal of Nuclear Medicine. 64(6). 896–901. 10 indexed citations

Sibille, Ludovic, Maythinee Chantadisai, Andrei Gafita, et al.. (2021). Whole-body uptake classification and prostate cancer staging in 68Ga-PSMA-11 PET/CT using dual-tracer learning. European Journal of Nuclear Medicine and Molecular Imaging. 49(2). 517–526. 31 indexed citations

Langbein, Thomas, Alexander Wurzer, Andrei Gafita, et al.. (2021). The Influence of Specific Activity on the Biodistribution of ¹⁸F-rhPSMA-7.3: A Retrospective Analysis of Clinical Positron Emission Tomography Data. Journal of Nuclear Medicine. 63(5). jnumed.121.262471–jnumed.121.262471. 7 indexed citations

Würnschimmel, Christoph, Thomas Langbein, Katja Steiger, et al.. (2021). PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Research. 11(1). 76–76. 17 indexed citations

Wang, Hui, Matthias Eiber, & Thomas Langbein. (2020). A rare case of polyostotic fibrous dysplasia detected on 18F-rhPSMA-7 PET/CT. European Journal of Nuclear Medicine and Molecular Imaging. 47(12). 2927–2929. 1 indexed citations

10.

Chantadisai, Maythinee, Martin Krönke, Isabel Rauscher, et al.. (2020). Positive predictive value and correct detection rate of ¹⁸F-rhPSMA-7 PET in biochemically recurrent prostate cancer validated by composite reference standard. Journal of Nuclear Medicine. 62(7). jnumed.120.255661–jnumed.120.255661. 6 indexed citations

11.

Langbein, Thomas, et al.. (2019). Effective Trade-off between Response and Toxicity by Using a Combination of Ac-225 and Lu-177 Labelled PSMA-617 for Progressive End-Stage Metastatic Prostate Cancer. Nuklearmedizin - NuclearMedicine. 58. 5 indexed citations

12.

Zhang, Jingjing, Harshad Kulkarni, Aviral Singh, et al.. (2019). ¹⁷⁷Lu-PSMA-617 Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer Patients with a Single Functioning Kidney. Journal of Nuclear Medicine. 60(11). 1579–1586. 32 indexed citations

13.

Eiber, Matthias, Markus Kroenke, Alexander Wurzer, et al.. (2019). ¹⁸F-rhPSMA-7 PET for the Detection of Biochemical Recurrence of Prostate Cancer After Radical Prostatectomy. Journal of Nuclear Medicine. 61(5). 696–701. 60 indexed citations

14.

Langbein, Thomas, et al.. (2019). Combined PRLT using Ac-225 and Lu-177 labeled PSMA-617 (TANDEM-PRLT) in end-stage metastatic prostate cancer: a concept to reduce salivary gland toxicity?. Nuklearmedizin - NuclearMedicine. 58. 5 indexed citations

15.

Oh, So Won, Alexander Wurzer, Eugene Teoh, et al.. (2019). Quantitative and Qualitative Analyses of Biodistribution and PET Image Quality of a Novel Radiohybrid PSMA, ¹⁸F-rhPSMA-7, in Patients with Prostate Cancer. Journal of Nuclear Medicine. 61(5). 702–709. 38 indexed citations

16.

Langbein, Thomas, et al.. (2019). Efficacy of Detoxsan^®powder on diarrhea caused by gastrointestinal neuroendocrine tumors. World Journal of Gastroenterology. 25(17). 2133–2143. 4 indexed citations

17.

Langbein, Thomas, et al.. (2018). Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies. Journal of Nuclear Medicine. 59(8). 1172–1173. 69 indexed citations

18.

Baum, Richard P., Thomas Langbein, Aviral Singh, et al.. (2018). Injection of Botulinum Toxin for Preventing Salivary Gland Toxicity after PSMA Radioligand Therapy: an Empirical Proof of a Promising Concept. Nuclear Medicine and Molecular Imaging. 52(1). 80–81. 65 indexed citations

19.

Singh, Aviral, Harshad Kulkarni, Thomas Langbein, et al.. (2018). PET/CT imaging of somatostatin receptor expressing solid tumors with the novel somatotostatin receptor antagonist 68Ga-NODAGA-LM3. 59. 42–42. 2 indexed citations

20.

Langbein, Thomas, et al.. (1999). Volatile anaesthetics and the atmosphere: atmospheric lifetimes and atmospheric effects of halothane, enflurane, isoflurane, desflurane and sevoflurane. British Journal of Anaesthesia. 82(1). 66–73. 94 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact